# BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).

> **NCT03227263** · PHASE3 · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 24 (actual)

## Conditions studied

- Rendu Osler Disease
- Telangiectasia, Hereditary Hemorrhagic

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** sodium chloride 0.9%

## Key facts

- **NCT ID:** NCT03227263
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-28
- **Primary completion:** 2020-05-15
- **Final completion:** 2020-05-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03227263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03227263, "BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03227263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*